Jefferies is cutting its price target on Orasure (OSUR -13.3%) on the back of yesterdays weaker than anticipated FY13 guidance. The firm cites lower base business expectations, but reiterates that the guidance shortfall is not related to tempered expectations surrounding new product launches. It says that FY13 revenue forecasts for OSUR's U.S. HCV & OTC HIV markets are unchanged, and reiterates a Buy on the shares. Read more on OSUR's earnings call here: Earnings Call Transcript.
Jefferies is cutting its price target on Orasure (OSUR -13.3%) on the back of yesterdays weaker...
From other sites
Video at CNBC.com (May 19, 2015)
at CNBC.com (Nov 19, 2012)
at CNBC.com (Oct 23, 2012)
at CNBC.com (Oct 8, 2012)
at CNBC.com (Jul 13, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs